85710:BORRELIA BURGDORFERI IgG and IgM ANTIBODIES

Print View Attached Docs:
85710:BORRELIA BURGDORFERI IgG and IgM ANTIBODIES
Alias Names: B. Burgdorferi / Lyme Disease
Methodology: Enzyme Immunoassay (EIA)
Edit Date: 12/29/2010
Performed: Tuesday-Saturday
Released: 24 hours after setup at PeaceHealth Laboratories’ reference lab.
CPT Code: 86618-90 x2
Specimen Collection Details
Collection: One 7.5 mL serum separator tube (SST).
Handling: Allow to clot, centrifuge and separate serum into a plastic vial. Refrigerate.
Stability: 7 days ambient, 14 days refrigerated, or 2 months frozen.
Standard Volume: 2 mL serum.
Minimum Volume: 0.5 mL serum.
Transport: Refrigerated.
Comments: Paired testing of acute and convalescent specimens is recommended. A Rapid Plasma Reagin (RPR) is performed at no charge on all specimens positive for Borrelia burgdorferi antibodies by enzyme immunoassay to exclude potential cross-reactions with syphilis.

Reference Range:
<.80 Index
Whole-cell sonicate (WCS) Borrelia burgdorferi antigens are utilized to measure both IgM and IgG antibody responses to B. burgdorferi in human serum, using an enzyme-immunoassay methodology (EIA). This test is used as a screen in a two-tier test algorithm proposed by the CDC for assessment of exposure to B. burgdorferi during early- and late-stage disease. For determination of early-stage Lyme disease (within the first 4 weeks of onset of erythema migrans), both IgM and IgG antibody detection should be evaluated. For late-stage Lyme disease (after 4 weeks of onset of erythema migrans), only IgG antibody detection should be evaluated. All IgM and IgG EIA positive results should be confirmed using the second tier immunoblot (IB) method.